InvestSMART

Entropy Neurodynamics Limited (ASX:ENP)

ALERT: Price-sensitive ASX Announcement for ENP
Current share price for ENP : $0.036 0.005 (16.13%)+
Announcement
Release
15 Jun 2026 9:55AM
Price at Release
$0.031
Full Release
download
Summary
Entropy Neurodynamics Limited announced the progression of its TRP-8803 program for Binge Eating Disorder, following a favorable review from the independent Data Safety Monitoring Board (DSMB). The DSMB recommended advancing to Cohort 2 of the Phase 2 clinical trial without protocol modifications, validating the safety and tolerability of TRP-8803 in the first cohort. TRP-8803, an IV-infused psilocin formulation, is designed to offer a controlled and reproducible psychedelic experience, addressing limitations of oral psilocybin. With no serious adverse reactions in Cohort 1, the trial now proceeds with a 60-minute infusion regimen for Cohort 2. This milestone supports Entropy's strategy in precision-controlled psychedelic medicine, with Cohort 2 results expected in Q4CY2026.
Key Points
  • DSMB recommended the progression of TRP-8803 to Cohort 2 without protocol modifications.
  • TRP-8803 demonstrated favorable safety and tolerability in Cohort 1.
  • No serious adverse reactions were reported, and all participants completed dosing.
  • TRP-8803 offers a controlled psychedelic experience via IV infusion, overcoming oral psilocybin's limitations.
  • Cohort 2 will use a 60-minute infusion regimen, anticipated to complete in Q3CY2026.
  • The DSMB's recommendation supports Entropy's broader strategy in psychedelic medicine.
  • Topline results for Cohort 1 are expected in early July 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.